Fenghuang Zhan
Concepts (526)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 126 | 2024 | 3024 | 9.650 |
Why?
| Drug Resistance, Neoplasm | 25 | 2020 | 309 | 3.450 |
Why?
| Gene Expression Regulation, Neoplastic | 51 | 2022 | 867 | 3.250 |
Why?
| Gene Expression Profiling | 40 | 2023 | 1138 | 2.690 |
Why?
| Cell Proliferation | 25 | 2022 | 1099 | 2.320 |
Why?
| Antineoplastic Agents | 29 | 2020 | 1295 | 2.180 |
Why?
| Cell Line, Tumor | 42 | 2023 | 1542 | 1.880 |
Why?
| Plasma Cells | 20 | 2023 | 238 | 1.860 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 7 | 2023 | 108 | 1.810 |
Why?
| Neoplastic Stem Cells | 7 | 2020 | 103 | 1.780 |
Why?
| Pyrazines | 19 | 2023 | 203 | 1.690 |
Why?
| Lymphoma, B-Cell | 5 | 2021 | 62 | 1.510 |
Why?
| Boronic Acids | 17 | 2014 | 197 | 1.460 |
Why?
| Apoptosis | 17 | 2022 | 1306 | 1.370 |
Why?
| Mice | 42 | 2024 | 6436 | 1.330 |
Why?
| Paraproteinemias | 8 | 2018 | 79 | 1.310 |
Why?
| Neoplasm Proteins | 7 | 2021 | 367 | 1.240 |
Why?
| Bone Resorption | 5 | 2023 | 326 | 1.240 |
Why?
| Humans | 142 | 2024 | 54132 | 1.220 |
Why?
| Osteolysis | 4 | 2022 | 88 | 1.190 |
Why?
| B-Lymphocytes | 7 | 2021 | 176 | 1.110 |
Why?
| Prognosis | 34 | 2024 | 2116 | 1.100 |
Why?
| Cell Cycle Proteins | 4 | 2023 | 198 | 1.090 |
Why?
| Animals | 51 | 2024 | 14435 | 1.060 |
Why?
| T-Lymphocytes | 8 | 2024 | 370 | 1.050 |
Why?
| Ubiquitination | 3 | 2021 | 47 | 1.020 |
Why?
| Proteasome Inhibitors | 7 | 2020 | 110 | 0.980 |
Why?
| Signal Transduction | 21 | 2023 | 1754 | 0.920 |
Why?
| Hematopoietic Stem Cell Transplantation | 5 | 2024 | 570 | 0.890 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 131 | 0.880 |
Why?
| MicroRNAs | 7 | 2022 | 387 | 0.860 |
Why?
| Antigens, CD | 7 | 2015 | 242 | 0.760 |
Why?
| CDC2-CDC28 Kinases | 3 | 2015 | 15 | 0.720 |
Why?
| Carrier Proteins | 3 | 2017 | 360 | 0.710 |
Why?
| Cation Transport Proteins | 2 | 2019 | 28 | 0.700 |
Why?
| Ubiquitins | 2 | 2016 | 40 | 0.670 |
Why?
| Cyclin-Dependent Kinases | 2 | 2010 | 35 | 0.670 |
Why?
| Glycolysis | 3 | 2022 | 70 | 0.670 |
Why?
| Mice, Inbred NOD | 5 | 2020 | 99 | 0.670 |
Why?
| Up-Regulation | 6 | 2020 | 514 | 0.660 |
Why?
| Disease Progression | 17 | 2023 | 915 | 0.660 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2018 | 41 | 0.650 |
Why?
| Proto-Oncogene Proteins c-akt | 5 | 2023 | 176 | 0.630 |
Why?
| Chromosome Aberrations | 6 | 2023 | 315 | 0.630 |
Why?
| STAT3 Transcription Factor | 4 | 2016 | 88 | 0.610 |
Why?
| Pyrimidines | 3 | 2015 | 196 | 0.610 |
Why?
| Iron | 2 | 2017 | 158 | 0.610 |
Why?
| Pyruvate Kinase | 1 | 2017 | 8 | 0.600 |
Why?
| Ascorbic Acid | 1 | 2017 | 33 | 0.600 |
Why?
| Cell Survival | 10 | 2020 | 661 | 0.590 |
Why?
| RNA Splicing | 1 | 2017 | 38 | 0.590 |
Why?
| Oligonucleotide Array Sequence Analysis | 17 | 2014 | 473 | 0.590 |
Why?
| Cell Differentiation | 8 | 2023 | 717 | 0.580 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1061 | 0.580 |
Why?
| Cyclopentanes | 1 | 2015 | 13 | 0.540 |
Why?
| Down-Regulation | 9 | 2019 | 392 | 0.540 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 96 | 0.530 |
Why?
| Thalidomide | 10 | 2023 | 398 | 0.530 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 27 | 0.520 |
Why?
| Osteoclasts | 7 | 2023 | 472 | 0.500 |
Why?
| Protein-Tyrosine Kinases | 1 | 2015 | 100 | 0.500 |
Why?
| Dexamethasone | 7 | 2024 | 448 | 0.500 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2020 | 21 | 0.500 |
Why?
| Hematologic Neoplasms | 1 | 2015 | 99 | 0.470 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 28 | 0.470 |
Why?
| B-Cell Maturation Antigen | 2 | 2024 | 63 | 0.470 |
Why?
| Cystatin M | 2 | 2024 | 21 | 0.470 |
Why?
| Models, Biological | 5 | 2018 | 824 | 0.450 |
Why?
| Glucuronidase | 4 | 2018 | 48 | 0.440 |
Why?
| Antigens, Neoplasm | 6 | 2014 | 170 | 0.440 |
Why?
| Flow Cytometry | 8 | 2018 | 548 | 0.440 |
Why?
| Antibodies, Bispecific | 2 | 2023 | 38 | 0.430 |
Why?
| Tumor Microenvironment | 4 | 2023 | 207 | 0.400 |
Why?
| Predictive Value of Tests | 5 | 2016 | 1053 | 0.400 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.400 |
Why?
| Arsenicals | 1 | 2010 | 13 | 0.390 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 21 | 0.390 |
Why?
| Oxides | 1 | 2010 | 18 | 0.390 |
Why?
| RNA, Messenger | 11 | 2021 | 1222 | 0.390 |
Why?
| Immunotherapy, Adoptive | 2 | 2024 | 130 | 0.390 |
Why?
| Mice, Transgenic | 6 | 2021 | 662 | 0.390 |
Why?
| Female | 41 | 2023 | 28437 | 0.380 |
Why?
| Janus Kinase 1 | 1 | 2010 | 20 | 0.380 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 83 | 0.370 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 26 | 0.370 |
Why?
| Male | 32 | 2023 | 27350 | 0.370 |
Why?
| Killer Cells, Natural | 4 | 2015 | 107 | 0.370 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 102 | 0.360 |
Why?
| DNA-Binding Proteins | 4 | 2021 | 463 | 0.360 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 682 | 0.360 |
Why?
| Early Growth Response Protein 1 | 1 | 2009 | 42 | 0.360 |
Why?
| Transcription Factors | 6 | 2022 | 619 | 0.340 |
Why?
| Oligopeptides | 3 | 2015 | 95 | 0.340 |
Why?
| Tretinoin | 1 | 2009 | 59 | 0.340 |
Why?
| Syndecan-1 | 5 | 2017 | 82 | 0.340 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2019 | 219 | 0.340 |
Why?
| Transplantation, Autologous | 4 | 2024 | 476 | 0.330 |
Why?
| Osteogenesis | 5 | 2023 | 381 | 0.320 |
Why?
| NF-kappa B | 3 | 2018 | 336 | 0.320 |
Why?
| Genes, Neoplasm | 1 | 2008 | 36 | 0.320 |
Why?
| Tumor Cells, Cultured | 6 | 2020 | 483 | 0.320 |
Why?
| Microarray Analysis | 3 | 2018 | 83 | 0.310 |
Why?
| Antibodies | 3 | 2024 | 177 | 0.310 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2007 | 2 | 0.310 |
Why?
| Chromosomes, Human, Pair 1 | 4 | 2023 | 113 | 0.310 |
Why?
| Neoplasms, Plasma Cell | 2 | 2023 | 32 | 0.300 |
Why?
| Immunologic Factors | 5 | 2015 | 130 | 0.300 |
Why?
| Interleukin-6 | 3 | 2019 | 315 | 0.300 |
Why?
| Pyrazoles | 2 | 2020 | 112 | 0.300 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2008 | 251 | 0.300 |
Why?
| Small Molecule Libraries | 2 | 2019 | 72 | 0.300 |
Why?
| Neoplasms | 2 | 2015 | 1309 | 0.290 |
Why?
| Aged | 23 | 2023 | 10059 | 0.280 |
Why?
| Mice, SCID | 9 | 2018 | 196 | 0.280 |
Why?
| Risk Factors | 11 | 2018 | 3936 | 0.260 |
Why?
| Genomics | 2 | 2023 | 309 | 0.260 |
Why?
| Survival Rate | 8 | 2020 | 955 | 0.260 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 50 | 0.250 |
Why?
| Bone Diseases | 4 | 2016 | 108 | 0.250 |
Why?
| Enzyme Inhibitors | 4 | 2019 | 456 | 0.250 |
Why?
| Ferritins | 1 | 2024 | 31 | 0.240 |
Why?
| TNF Receptor-Associated Factor 3 | 2 | 2022 | 14 | 0.240 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.240 |
Why?
| X-Ray Microtomography | 1 | 2024 | 83 | 0.240 |
Why?
| Histocompatibility Antigens Class I | 2 | 2015 | 52 | 0.240 |
Why?
| Melphalan | 3 | 2023 | 181 | 0.240 |
Why?
| Genes, myc | 3 | 2019 | 47 | 0.230 |
Why?
| Middle Aged | 22 | 2021 | 13094 | 0.230 |
Why?
| Intercellular Signaling Peptides and Proteins | 4 | 2007 | 123 | 0.230 |
Why?
| Gene Knockdown Techniques | 3 | 2018 | 127 | 0.230 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2022 | 5 | 0.220 |
Why?
| Bone and Bones | 2 | 2021 | 523 | 0.220 |
Why?
| Neutropenia | 1 | 2023 | 120 | 0.220 |
Why?
| Periodontitis | 1 | 2022 | 10 | 0.220 |
Why?
| Recurrence | 7 | 2018 | 692 | 0.220 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2016 | 577 | 0.220 |
Why?
| Protein Binding | 2 | 2018 | 743 | 0.220 |
Why?
| Case-Control Studies | 8 | 2020 | 1242 | 0.210 |
Why?
| Protein Stability | 2 | 2020 | 44 | 0.210 |
Why?
| Reactive Oxygen Species | 4 | 2017 | 494 | 0.210 |
Why?
| Kaplan-Meier Estimate | 5 | 2016 | 514 | 0.200 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 1 | 0.200 |
Why?
| Nuclear Factor 90 Proteins | 1 | 2021 | 1 | 0.200 |
Why?
| Osteoporosis | 1 | 2023 | 165 | 0.200 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2020 | 100 | 0.200 |
Why?
| Arthritis, Rheumatoid | 1 | 2022 | 129 | 0.200 |
Why?
| Antibodies, Monoclonal | 3 | 2013 | 560 | 0.200 |
Why?
| RANK Ligand | 1 | 2022 | 183 | 0.200 |
Why?
| In Situ Hybridization, Fluorescence | 4 | 2023 | 277 | 0.200 |
Why?
| Hippurates | 1 | 2021 | 10 | 0.200 |
Why?
| Phenylpropionates | 1 | 2021 | 12 | 0.200 |
Why?
| Venous Thromboembolism | 3 | 2011 | 75 | 0.200 |
Why?
| Proteolysis | 3 | 2017 | 102 | 0.190 |
Why?
| Bone Neoplasms | 2 | 2015 | 191 | 0.190 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 208 | 0.190 |
Why?
| Colorectal Neoplasms | 2 | 2022 | 237 | 0.190 |
Why?
| Antigens, CD20 | 2 | 2014 | 4 | 0.190 |
Why?
| Protease Inhibitors | 3 | 2011 | 64 | 0.190 |
Why?
| Colonic Neoplasms | 1 | 2022 | 165 | 0.190 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2021 | 55 | 0.190 |
Why?
| Cell Cycle | 4 | 2010 | 274 | 0.190 |
Why?
| Cell Movement | 2 | 2015 | 276 | 0.190 |
Why?
| Membrane Proteins | 3 | 2017 | 391 | 0.190 |
Why?
| Neoplasm Metastasis | 4 | 2015 | 252 | 0.190 |
Why?
| Chromosomal Instability | 3 | 2021 | 18 | 0.190 |
Why?
| Evolution, Molecular | 1 | 2021 | 103 | 0.190 |
Why?
| Disease-Free Survival | 7 | 2016 | 488 | 0.190 |
Why?
| Bone Marrow | 5 | 2020 | 415 | 0.190 |
Why?
| Cytotoxicity, Immunologic | 4 | 2015 | 62 | 0.180 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 70 | 0.180 |
Why?
| Oxidative Stress | 4 | 2016 | 953 | 0.180 |
Why?
| Antigens, CD19 | 2 | 2018 | 19 | 0.180 |
Why?
| Treatment Outcome | 12 | 2020 | 5596 | 0.180 |
Why?
| Membrane Glycoproteins | 5 | 2009 | 269 | 0.180 |
Why?
| Bone Marrow Cells | 3 | 2015 | 234 | 0.180 |
Why?
| Gene Expression | 3 | 2017 | 667 | 0.180 |
Why?
| Adult | 19 | 2021 | 14196 | 0.180 |
Why?
| Tumor Suppressor Proteins | 2 | 2019 | 141 | 0.180 |
Why?
| Neoplasm Recurrence, Local | 1 | 2024 | 643 | 0.180 |
Why?
| Time Factors | 8 | 2021 | 3223 | 0.180 |
Why?
| Clinical Trials as Topic | 1 | 2022 | 489 | 0.180 |
Why?
| DNA, Single-Stranded | 1 | 2020 | 71 | 0.180 |
Why?
| Oncogene Proteins | 1 | 2019 | 16 | 0.170 |
Why?
| Cluster Analysis | 4 | 2009 | 250 | 0.170 |
Why?
| Transplantation, Heterologous | 2 | 2017 | 76 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 267 | 0.170 |
Why?
| NF-E2-Related Factor 2 | 1 | 2019 | 63 | 0.170 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2019 | 27 | 0.170 |
Why?
| Mitosis | 3 | 2015 | 107 | 0.170 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 29 | 0.170 |
Why?
| rab GTP-Binding Proteins | 1 | 2019 | 39 | 0.170 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 55 | 0.170 |
Why?
| Drug Tolerance | 1 | 2018 | 60 | 0.170 |
Why?
| Pyridines | 1 | 2019 | 137 | 0.160 |
Why?
| Neovascularization, Pathologic | 3 | 2009 | 172 | 0.160 |
Why?
| Blotting, Western | 3 | 2015 | 685 | 0.160 |
Why?
| Retrospective Studies | 6 | 2024 | 6387 | 0.160 |
Why?
| beta Catenin | 2 | 2015 | 102 | 0.150 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 428 | 0.150 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2017 | 4 | 0.150 |
Why?
| Mice, Knockout | 4 | 2023 | 941 | 0.150 |
Why?
| Aerobiosis | 1 | 2017 | 16 | 0.150 |
Why?
| Hydroxamic Acids | 2 | 2014 | 47 | 0.150 |
Why?
| Microfilament Proteins | 1 | 2017 | 47 | 0.150 |
Why?
| Thyroid Hormones | 1 | 2017 | 18 | 0.150 |
Why?
| Onium Compounds | 1 | 2016 | 14 | 0.150 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 61 | 0.150 |
Why?
| Deoxyglucose | 1 | 2016 | 27 | 0.150 |
Why?
| Organophosphorus Compounds | 1 | 2016 | 17 | 0.150 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2014 | 56 | 0.150 |
Why?
| Inhibitor of Apoptosis Proteins | 3 | 2015 | 21 | 0.140 |
Why?
| Survival Analysis | 6 | 2020 | 739 | 0.140 |
Why?
| RNA Interference | 2 | 2015 | 195 | 0.140 |
Why?
| Gene Deletion | 2 | 2008 | 296 | 0.140 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 48 | 0.140 |
Why?
| Ribosomal Proteins | 1 | 2016 | 32 | 0.140 |
Why?
| Pancreatic Neoplasms | 1 | 2019 | 235 | 0.140 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 18 | 0.140 |
Why?
| Cell Death | 1 | 2016 | 228 | 0.140 |
Why?
| Proto-Oncogene Proteins | 2 | 2009 | 163 | 0.140 |
Why?
| Aged, 80 and over | 7 | 2021 | 3442 | 0.140 |
Why?
| Macrophages | 2 | 2022 | 401 | 0.140 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 87 | 0.130 |
Why?
| Gene Dosage | 2 | 2013 | 91 | 0.130 |
Why?
| Polysaccharides | 1 | 2015 | 57 | 0.130 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 47 | 0.130 |
Why?
| Receptors, Transferrin | 1 | 2015 | 17 | 0.130 |
Why?
| Side-Population Cells | 1 | 2015 | 3 | 0.130 |
Why?
| Lentivirus | 1 | 2015 | 18 | 0.130 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.130 |
Why?
| Serine Endopeptidases | 2 | 2006 | 57 | 0.130 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 133 | 0.130 |
Why?
| Adenine | 1 | 2015 | 45 | 0.130 |
Why?
| Caspase 3 | 2 | 2022 | 136 | 0.130 |
Why?
| Cell Lineage | 1 | 2014 | 94 | 0.130 |
Why?
| Serum | 1 | 2014 | 40 | 0.130 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 35 | 0.130 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 97 | 0.120 |
Why?
| Piperidines | 1 | 2015 | 102 | 0.120 |
Why?
| Superoxide Dismutase | 1 | 2014 | 125 | 0.120 |
Why?
| Tumor Burden | 3 | 2020 | 142 | 0.120 |
Why?
| HLA Antigens | 1 | 2014 | 55 | 0.120 |
Why?
| Cyclins | 3 | 2015 | 55 | 0.120 |
Why?
| Alkaline Phosphatase | 2 | 2011 | 101 | 0.120 |
Why?
| Glycoproteins | 1 | 2014 | 132 | 0.120 |
Why?
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2013 | 17 | 0.120 |
Why?
| Leukemia, Plasma Cell | 1 | 2013 | 34 | 0.120 |
Why?
| Lactate Dehydrogenases | 1 | 2013 | 2 | 0.120 |
Why?
| Repressor Proteins | 4 | 2015 | 167 | 0.120 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 75 | 0.110 |
Why?
| Genome, Human | 2 | 2021 | 132 | 0.110 |
Why?
| Phenotype | 4 | 2009 | 822 | 0.110 |
Why?
| Scavenger Receptors, Class A | 1 | 2013 | 38 | 0.110 |
Why?
| Leukemia | 1 | 2013 | 70 | 0.110 |
Why?
| bcl-X Protein | 1 | 2013 | 59 | 0.110 |
Why?
| Heat-Shock Proteins | 1 | 2013 | 86 | 0.110 |
Why?
| Follow-Up Studies | 5 | 2024 | 2384 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 1478 | 0.110 |
Why?
| RNA, Neoplasm | 3 | 2007 | 55 | 0.110 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2012 | 47 | 0.110 |
Why?
| Disease Models, Animal | 4 | 2020 | 1645 | 0.110 |
Why?
| RNA, Small Interfering | 2 | 2010 | 254 | 0.110 |
Why?
| Forkhead Transcription Factors | 2 | 2023 | 118 | 0.110 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2011 | 28 | 0.100 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2020 | 142 | 0.100 |
Why?
| Activated Protein C Resistance | 1 | 2011 | 10 | 0.100 |
Why?
| Factor V | 1 | 2011 | 11 | 0.100 |
Why?
| Protein Isoforms | 2 | 2009 | 125 | 0.100 |
Why?
| Acetylcysteine | 1 | 2011 | 118 | 0.100 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.100 |
Why?
| Cell Growth Processes | 1 | 2010 | 24 | 0.100 |
Why?
| HLA-A Antigens | 2 | 2007 | 13 | 0.100 |
Why?
| Glucocorticoids | 1 | 2013 | 276 | 0.100 |
Why?
| Gene Silencing | 2 | 2007 | 127 | 0.090 |
Why?
| Alleles | 2 | 2021 | 278 | 0.090 |
Why?
| Thrombosis | 1 | 2012 | 243 | 0.090 |
Why?
| Immunophenotyping | 5 | 2010 | 117 | 0.090 |
Why?
| K562 Cells | 3 | 2016 | 47 | 0.090 |
Why?
| Epigenesis, Genetic | 2 | 2023 | 399 | 0.090 |
Why?
| Cells, Cultured | 6 | 2015 | 1755 | 0.090 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 78 | 0.090 |
Why?
| Syndecans | 2 | 2006 | 43 | 0.090 |
Why?
| Chromosome Mapping | 2 | 2006 | 176 | 0.090 |
Why?
| Bone Remodeling | 1 | 2010 | 180 | 0.090 |
Why?
| Thromboembolism | 1 | 2009 | 56 | 0.090 |
Why?
| Recombinant Proteins | 1 | 2010 | 574 | 0.090 |
Why?
| Proteoglycans | 2 | 2006 | 97 | 0.080 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 13 | 0.080 |
Why?
| Receptors, Immunologic | 1 | 2008 | 37 | 0.080 |
Why?
| ras Proteins | 2 | 2020 | 69 | 0.080 |
Why?
| Neoplasm Transplantation | 2 | 2020 | 94 | 0.080 |
Why?
| G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 7 | 0.080 |
Why?
| Genes, abl | 1 | 2007 | 1 | 0.080 |
Why?
| Adoptive Transfer | 1 | 2007 | 37 | 0.080 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2007 | 29 | 0.080 |
Why?
| Angiogenesis Inhibitors | 1 | 2009 | 203 | 0.080 |
Why?
| Patient Selection | 1 | 2009 | 286 | 0.080 |
Why?
| Mutation | 3 | 2021 | 1499 | 0.080 |
Why?
| Breast Neoplasms | 2 | 2007 | 1248 | 0.080 |
Why?
| HEK293 Cells | 2 | 2019 | 248 | 0.080 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 78 | 0.070 |
Why?
| Translocation, Genetic | 3 | 2021 | 286 | 0.070 |
Why?
| Cyclin D | 1 | 2006 | 20 | 0.070 |
Why?
| Chromosome Banding | 1 | 2006 | 27 | 0.070 |
Why?
| Cancer Vaccines | 1 | 2007 | 103 | 0.070 |
Why?
| Drug Evaluation, Preclinical | 2 | 2021 | 158 | 0.070 |
Why?
| Caspases | 1 | 2007 | 147 | 0.070 |
Why?
| Maf Transcription Factors, Large | 1 | 2005 | 1 | 0.070 |
Why?
| Models, Genetic | 1 | 2006 | 209 | 0.070 |
Why?
| DNA Damage | 1 | 2008 | 358 | 0.070 |
Why?
| Peptides | 1 | 2007 | 278 | 0.070 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 209 | 0.070 |
Why?
| Doxorubicin | 2 | 2018 | 258 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 177 | 0.070 |
Why?
| Cyclin D1 | 1 | 2005 | 59 | 0.070 |
Why?
| Protein Kinases | 1 | 2005 | 88 | 0.070 |
Why?
| Antibody Formation | 1 | 2005 | 69 | 0.060 |
Why?
| Protein Biosynthesis | 2 | 2003 | 273 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 107 | 0.060 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2004 | 74 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 2021 | 0.060 |
Why?
| Carcinoma, Papillary | 1 | 2004 | 65 | 0.060 |
Why?
| Base Sequence | 3 | 2015 | 732 | 0.060 |
Why?
| Transfection | 2 | 2020 | 410 | 0.060 |
Why?
| Drug Synergism | 2 | 2014 | 171 | 0.060 |
Why?
| Jurkat Cells | 2 | 2014 | 34 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2019 | 368 | 0.060 |
Why?
| Zebrafish Proteins | 1 | 2003 | 23 | 0.060 |
Why?
| Extracellular Matrix Proteins | 1 | 2004 | 75 | 0.060 |
Why?
| Transcription, Genetic | 1 | 2005 | 419 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 575 | 0.060 |
Why?
| Integrin beta Chains | 1 | 2023 | 14 | 0.060 |
Why?
| Integrins | 1 | 2023 | 36 | 0.060 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2003 | 41 | 0.060 |
Why?
| Oxidative Phosphorylation | 1 | 2023 | 60 | 0.060 |
Why?
| Cytogenetic Analysis | 1 | 2023 | 89 | 0.060 |
Why?
| Porphyromonas gingivalis | 1 | 2022 | 3 | 0.060 |
Why?
| Macrophage Activation | 1 | 2022 | 29 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2023 | 151 | 0.050 |
Why?
| Geography | 1 | 2022 | 81 | 0.050 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 216 | 0.050 |
Why?
| Chromatin | 1 | 2023 | 155 | 0.050 |
Why?
| Uterine Cervical Neoplasms | 1 | 2005 | 276 | 0.050 |
Why?
| Inflammasomes | 1 | 2022 | 60 | 0.050 |
Why?
| Diploidy | 3 | 2007 | 30 | 0.050 |
Why?
| DNA, Neoplasm | 1 | 2002 | 172 | 0.050 |
Why?
| Models, Animal | 2 | 2015 | 255 | 0.050 |
Why?
| Mutation Rate | 1 | 2021 | 40 | 0.050 |
Why?
| DNA Primers | 2 | 2015 | 225 | 0.050 |
Why?
| Clone Cells | 1 | 2021 | 90 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.050 |
Why?
| Genes, Tumor Suppressor | 1 | 2021 | 85 | 0.050 |
Why?
| HCT116 Cells | 1 | 2020 | 27 | 0.050 |
Why?
| Proteins | 1 | 2003 | 382 | 0.050 |
Why?
| DNA Copy Number Variations | 1 | 2021 | 114 | 0.050 |
Why?
| Wnt Signaling Pathway | 1 | 2021 | 94 | 0.050 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 56 | 0.050 |
Why?
| Double-Blind Method | 2 | 2014 | 747 | 0.050 |
Why?
| Ovarian Neoplasms | 1 | 2004 | 471 | 0.050 |
Why?
| Cytokines | 3 | 2009 | 678 | 0.050 |
Why?
| Gene Knockout Techniques | 1 | 2019 | 45 | 0.040 |
Why?
| Immunohistochemistry | 3 | 2009 | 1097 | 0.040 |
Why?
| Drug Discovery | 1 | 2020 | 89 | 0.040 |
Why?
| Protein Phosphatase 2 | 1 | 2019 | 6 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 179 | 0.040 |
Why?
| Enzyme Activators | 1 | 2019 | 8 | 0.040 |
Why?
| G1 Phase | 1 | 2019 | 19 | 0.040 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 15 | 0.040 |
Why?
| DNA | 1 | 2023 | 582 | 0.040 |
Why?
| Protein Conformation | 1 | 2019 | 227 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 259 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 284 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 646 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 206 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2020 | 428 | 0.040 |
Why?
| Immunotherapy | 1 | 2021 | 260 | 0.040 |
Why?
| Wnt Proteins | 2 | 2013 | 110 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 231 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2019 | 85 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 75 | 0.040 |
Why?
| DNA Methylation | 1 | 2023 | 575 | 0.040 |
Why?
| Phosphorylation | 1 | 2020 | 609 | 0.040 |
Why?
| Autophagy | 1 | 2020 | 202 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 36 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2022 | 1678 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 2022 | 1075 | 0.040 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2007 | 115 | 0.040 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2016 | 41 | 0.040 |
Why?
| Cell Hypoxia | 1 | 2016 | 89 | 0.040 |
Why?
| Biological Transport | 1 | 2016 | 192 | 0.040 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 24 | 0.040 |
Why?
| Drug Interactions | 1 | 2016 | 206 | 0.040 |
Why?
| Chronic Disease | 1 | 2019 | 611 | 0.040 |
Why?
| Models, Statistical | 2 | 2008 | 259 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 87 | 0.030 |
Why?
| Mitoxantrone | 1 | 2015 | 11 | 0.030 |
Why?
| Vidarabine | 1 | 2015 | 11 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2016 | 134 | 0.030 |
Why?
| Reoviridae | 1 | 2015 | 28 | 0.030 |
Why?
| Pharmacogenetics | 2 | 2006 | 55 | 0.030 |
Why?
| Cell Line | 2 | 2013 | 1166 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 55 | 0.030 |
Why?
| China | 1 | 2015 | 103 | 0.030 |
Why?
| Vincristine | 1 | 2015 | 98 | 0.030 |
Why?
| Neoplasm Staging | 2 | 2009 | 801 | 0.030 |
Why?
| Vaccination | 2 | 2007 | 293 | 0.030 |
Why?
| Prednisone | 1 | 2015 | 111 | 0.030 |
Why?
| Ligands | 1 | 2015 | 233 | 0.030 |
Why?
| Disulfiram | 1 | 2014 | 11 | 0.030 |
Why?
| Glutathione Peroxidase | 1 | 2014 | 28 | 0.030 |
Why?
| Cyclin B | 1 | 2014 | 5 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 130 | 0.030 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2015 | 171 | 0.030 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 22 | 0.030 |
Why?
| Microscopy, Fluorescence | 1 | 2015 | 196 | 0.030 |
Why?
| Glucose | 1 | 2016 | 353 | 0.030 |
Why?
| Risk Assessment | 2 | 2009 | 1363 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 53 | 0.030 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2013 | 12 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 119 | 0.030 |
Why?
| Lectins, C-Type | 1 | 2013 | 32 | 0.030 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 5 | 0.030 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 19 | 0.030 |
Why?
| Isoxazoles | 1 | 2013 | 16 | 0.030 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 21 | 0.030 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2013 | 36 | 0.030 |
Why?
| Sulfones | 1 | 2013 | 24 | 0.030 |
Why?
| Hedgehog Proteins | 1 | 2013 | 33 | 0.030 |
Why?
| Itraconazole | 1 | 2013 | 45 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 29 | 0.030 |
Why?
| Receptors, Glucocorticoid | 1 | 2013 | 48 | 0.030 |
Why?
| Glutathione | 1 | 2014 | 330 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 22 | 0.030 |
Why?
| Azacitidine | 1 | 2013 | 37 | 0.030 |
Why?
| ADP-ribosyl Cyclase | 2 | 2003 | 5 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 66 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 99 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 88 | 0.030 |
Why?
| Histone Deacetylases | 1 | 2013 | 48 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2013 | 132 | 0.030 |
Why?
| Hydrocortisone | 1 | 2013 | 161 | 0.030 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 140 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 157 | 0.030 |
Why?
| Prospective Studies | 2 | 2010 | 2607 | 0.030 |
Why?
| Radiation, Ionizing | 1 | 2013 | 121 | 0.030 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 50 | 0.030 |
Why?
| Osteoblasts | 2 | 2006 | 526 | 0.030 |
Why?
| Transcriptome | 1 | 2014 | 347 | 0.030 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.030 |
Why?
| Protein C | 1 | 2011 | 24 | 0.030 |
Why?
| Risk | 1 | 2011 | 343 | 0.020 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 81 | 0.020 |
Why?
| Databases as Topic | 1 | 2009 | 46 | 0.020 |
Why?
| Diphosphonates | 1 | 2010 | 94 | 0.020 |
Why?
| Lymphocytes | 1 | 2010 | 168 | 0.020 |
Why?
| Parathyroid Hormone | 1 | 2010 | 215 | 0.020 |
Why?
| Cytoskeleton | 1 | 2008 | 50 | 0.020 |
Why?
| STAT Transcription Factors | 1 | 2007 | 7 | 0.020 |
Why?
| Twins | 1 | 2007 | 32 | 0.020 |
Why?
| Cytological Techniques | 1 | 2007 | 14 | 0.020 |
Why?
| NF-kappa B p52 Subunit | 1 | 2007 | 6 | 0.020 |
Why?
| NF-kappa B p50 Subunit | 1 | 2007 | 16 | 0.020 |
Why?
| Genotype | 1 | 2009 | 607 | 0.020 |
Why?
| I-kappa B Kinase | 1 | 2007 | 30 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2007 | 12 | 0.020 |
Why?
| Karyotyping | 1 | 2007 | 93 | 0.020 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 72 | 0.020 |
Why?
| Antigen Presentation | 1 | 2007 | 28 | 0.020 |
Why?
| Benzamides | 1 | 2007 | 55 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 239 | 0.020 |
Why?
| Polysaccharide-Lyases | 1 | 2007 | 6 | 0.020 |
Why?
| Remission Induction | 1 | 2007 | 222 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2007 | 133 | 0.020 |
Why?
| Plasmids | 1 | 2007 | 180 | 0.020 |
Why?
| Tissue Culture Techniques | 1 | 2007 | 46 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.020 |
Why?
| Interferon-gamma | 1 | 2007 | 195 | 0.020 |
Why?
| Enzyme Activation | 1 | 2007 | 333 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 318 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2006 | 51 | 0.020 |
Why?
| Piperazines | 1 | 2007 | 117 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2007 | 115 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 271 | 0.020 |
Why?
| Dendritic Cells | 1 | 2007 | 142 | 0.020 |
Why?
| Receptors, Estrogen | 1 | 2007 | 133 | 0.020 |
Why?
| Chromosomes, Human | 1 | 2006 | 45 | 0.020 |
Why?
| Gelatinases | 1 | 2006 | 36 | 0.020 |
Why?
| Incidence | 1 | 2009 | 1084 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1133 | 0.020 |
Why?
| Endopeptidases | 1 | 2006 | 75 | 0.020 |
Why?
| Coculture Techniques | 1 | 2006 | 158 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 533 | 0.020 |
Why?
| Rabbits | 1 | 2006 | 440 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2007 | 694 | 0.020 |
Why?
| Cyclin D3 | 1 | 2005 | 6 | 0.020 |
Why?
| Cyclin D2 | 1 | 2005 | 20 | 0.020 |
Why?
| Trisomy | 1 | 2005 | 34 | 0.020 |
Why?
| Adipocytes | 1 | 2006 | 132 | 0.020 |
Why?
| Oligonucleotide Probes | 1 | 2004 | 22 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2006 | 428 | 0.020 |
Why?
| Epithelium | 1 | 2004 | 70 | 0.020 |
Why?
| Stem Cells | 1 | 2006 | 192 | 0.020 |
Why?
| Ovary | 1 | 2004 | 104 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2006 | 996 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2006 | 293 | 0.020 |
Why?
| Endothelial Cells | 1 | 2006 | 296 | 0.010 |
Why?
| Palatine Tonsil | 1 | 2003 | 12 | 0.010 |
Why?
| Databases, Factual | 1 | 2007 | 685 | 0.010 |
Why?
| RNA, Complementary | 1 | 2003 | 4 | 0.010 |
Why?
| Autocrine Communication | 1 | 2003 | 10 | 0.010 |
Why?
| Paracrine Communication | 1 | 2003 | 12 | 0.010 |
Why?
| Metaphase | 1 | 2003 | 54 | 0.010 |
Why?
| Melanoma-Specific Antigens | 1 | 2002 | 3 | 0.010 |
Why?
| NAD+ Nucleosidase | 1 | 2002 | 3 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 455 | 0.010 |
Why?
| Cell Separation | 1 | 2003 | 108 | 0.010 |
Why?
| Cell Communication | 1 | 2003 | 70 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 23 | 0.010 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2003 | 150 | 0.010 |
Why?
| Biopsy | 1 | 2005 | 694 | 0.010 |
Why?
| Immunoglobulins | 1 | 2002 | 89 | 0.010 |
Why?
| Cohort Studies | 1 | 2006 | 1549 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2005 | 1307 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 991 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2003 | 1603 | 0.010 |
Why?
|
|
Zhan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|